Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cromoglycate Clear all
Terminated Phase 2 Interventional

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

NCT04428775
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ALZT-OP1a (cromolyn)
Drug
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
La Jolla, California • Jacksonville, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)

NCT02566252
View directory record Official record
Conditions
Healthy
Interventions
PUL-042 Inhalation Solution, Cromolyn Sodium, Albuterol sulfate
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 2, 2026, 6:32 AM EDT
Not listed Phase 2 Interventional

Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

NCT05449444
View directory record Official record
Conditions
Mast Cell Activation Syndrome
Interventions
Masitinib 4.5 mg/kg/day, Placebo, Best supportive care, Masitinib 6.0 mg/kg/day
Drug · Other
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Weldon Spring, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

NCT02547818
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ALZT-OP1a, ALZT-OP1b, Placebo ALZT-OP1a, Placebo ALZT-OP1b
Drug · Other
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
55 Years to 79 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
69
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema

NCT01933464
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Cromolyn Sodium, Normal Saline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 2, 2026, 6:32 AM EDT
Not yet recruiting Phase 1 Interventional

Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer

NCT07675876
View directory record Official record
Conditions
Locally Advanced Non-Small Cell Lung Cancer, Lung Adenocarcinoma
Interventions
Cromolyn Sodium
Drug
Lead sponsor
Carcinex Inc
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Terminated Phase 2 Interventional Results available

Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis

NCT04846348
View directory record Official record
Conditions
Cutaneous Mastocytoses
Interventions
Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.
Combination Product
Lead sponsor
Joseph Butterfield
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers

NCT02482324
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ALZT-OP1a, ALZT-OP1b, Dry Powder Inhaler
Drug · Device
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
55 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2015 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 3 Interventional

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

NCT00814073
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
Masitinib, Placebo, Best Supportive Care
Drug · Other
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting Phase 2 Interventional

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg)
Drug
Lead sponsor
PhenoNet, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Early Phase 1 Interventional

Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction

NCT03167216
View directory record Official record
Conditions
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions
Cromolyn Sodium, Cetirizine Hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 80 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 4 Interventional Results available

Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis

NCT02371941
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
oral cromolyn sodium, Placebo
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
2 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 2, 2026, 6:32 AM EDT
Not yet recruiting Early Phase 1 Interventional

Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial

NCT07757555
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome (POTS), Dysautonomia, Orthostatic Intolerance, Autonomic Nervous System Diseases
Interventions
Guanfacine (GFC), Cromolyn Sodium, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

NCT03794076
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Cromoglycate, Placebo
Drug
Lead sponsor
Vishwajit Nimgaonkar, MD PhD
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Terminated Phase 3 Interventional

Cromolyn Sodium for Treatment of COVID-19 Pneumonia

NCT05077917
View directory record Official record
Conditions
COVID-19 Pneumonia, COVID-19 Respiratory Infection, Pneumonia, Viral
Interventions
Cromolyn Sodium, Placebo
Drug · Other
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting Phase 3 Interventional

Novel Strategies for Reducing Burn Scar Itch

NCT06801626
View directory record Official record
Conditions
Burn Scar, Itch Scarring, Wound
Interventions
Famotidine and 4% topical cromolyn sodium, Placebo
Combination Product · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers

NCT04570644
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease
Interventions
ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)
Drug
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
55 Years to 79 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 2, 2026, 6:32 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Cromolyn Detection of Silent Aspiration

NCT01841307
View directory record Official record
Conditions
Gastroesophageal Reflux, Respiratory Aspiration, Idiopathic Pulmonary Fibrosis, Lung Transplantation
Interventions
Cromolyn Sodium
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 2, 2026, 6:32 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Mast Cell Treatment in Post-tick Bite Illness (PTBI)

NCT07526558
View directory record Official record
Conditions
Post-tick Bite Illness, Mast Cell Stabilizer
Interventions
Ketotifen, fexofenadine, Cromolyn Sodium
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 2, 2026, 6:32 AM EDT